Lugano, Switzerland – 15 June 2018 – Groundbreaking research will be revealed at this year’s ESMO World Congress on Gastrointestinal Cancer (20-23 June, Barcelona, Spain), (1) celebrating 20 years of clinical progress in a group of diseases that affect both men and women worldwide.
Hepatocellular carcinoma, gastric cancer, colorectal cancer will be under the spotlight with results from the latest research in the field, ranging from chemotherapy through immunotherapy.
The Congress will bring together more than 3,500 professionals from across the globe willing to share pioneering research, innovative approaches, best practices and clinical insights in treating patients with cancers of the gastrointestinal tract: gastroenterologists, oncologists, pathologists, surgeons, clinical researchers, as well as patient advocates.
According to Congress Chair Eric Van Cutsem, “The research that will be presented at the ESMO 20th World Congress on Gastrointestinal Cancer proves to be some of the most impressive yet. I am confident that the exceptional programme will meet the high expectations of delegates coming from all over the world interested in learning the latest findings, engaging in productive exchange, and, most importantly, being guided by experts who can translate research into recommendations for daily patient care.”
Sessions in the programme (2) are devoted
Article originally posted at